Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 3Non-melanoma Skin Cancer 2Lung Neoplasms 2Keratosis, Actinic 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Respiratory Aspiration 1Prostatic Hyperplasia 1Pneumothorax 1Pleural Neoplasms 1Pleural Effusion 1Photosensitivity Disorders 1Pain, Postoperative 1Pain 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lower Urinary Tract Symptoms 1Hematuria 1Hand-Foot Syndrome 1Empyema, Pleural 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 104Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Diclofenac × Clear all
NCT01332617 2017-12-29

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

University of Louisville

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡